Latest Drugs, Latest Approval in CD38 monoclonal antibodies

What are CD38 monoclonal antibodies?

Monoclonal antibodies used in immunotherapy are produced artificially from a cell clone therefore consist of a single type of immunoglobulin. They are targeted towards antigenic determinant on antigens and bind to form a complex which can be used for a specific purpose. CD38 monoclonal antibodies target the CD38 surface antigen of hematopoietic cells, which is important for cell function. Once CD38 monoclonal antibodies bind to the antigen it inhibits tumour growth by interrupting CD38 functions and causes cell death. CD38 monoclonal antibodies are used to treat multiple myeloma.

Name Updated
Daratumumab and hyaluronidase (Daratumumab and hyaluronidase [ dar-a-toom-ue-mab-and-hye-al-ure-on-i-dase-o ]) 13-Aug-2023
Daratumumab (Daratumumab [ dar-a-toom-ue-mab ]) 13-Aug-2023
Isatuximab (Isatuximab [ eye-sa-tux-i-mab ]) 11-Aug-2023
Sarclisa (Isatuximab-irfc) 14-Jul-2023
Darzalex faspro (Daratumumab and hyaluronidase-fihj) 13-Jul-2023
Darzalex (Daratumumab [ dar-a-toom-ue-mab ]) 10-Jul-2023